AdvanCell Closes A$18M Series B Funding Led by Morningside
14.9.2022 17:16:00 EEST | Business Wire | Press release
AdvanCell, an Australian radiopharmaceutical company with a platform technology for a revolutionary cancer treatment called Targeted Alpha Therapy, announced today the closing of an A$18 million Series B financing round led by Morningside.
Andrew Adamovich, CEO and Founder of AdvanCell noted, “We are very pleased with our progress to date and delighted that we will continue our rapid growth with the support of our shareholders. We have had a long-term relationship with our lead investor, Morningside, and are excited to come closer still to our goal to 'Change the Course of Cancer Treatment.'”
Targeted Alpha Therapies represent the most exciting opportunity to treat currently untreatable cancers. The technology harnesses the natural decay and radiochemical properties of certain elements, in combination with specific targeting molecules, to selectively deliver cell-killing radiation to the tumour cell. AdvanCell believes this precise and powerful treatment will rapidly become a leading pillar of cancer treatment, providing treatments for diseases for which there are currently no effective options. Targeted Alpha Therapies demonstrate incredible efficacy, however widespread adoption and large commercial product launches require a scalable and reliable global isotope supply. AdvanCell was established to solve this problem.
AdvanCell’s ability to produce isotope on-demand and at scale, and its in-house radiopharmaceutical manufacturing expertise positions AdvanCell to play a leading role in this rapidly growing market. With additional support from NSW Health Medical Devices Fund and the Federal government’s Research & Development Tax Incentive, AdvanCell has developed a world-first scalable manufacturing platform to produce alpha-emitting isotopes for research, pre-clinical and clinical use and to advance its own and its partners' radiopharmaceutical products.
Anthony Aiudi from Morningside commented, “AdvanCell is leveraging its ability to make alpha isotopes at scale and in clinically useful amounts along with its radiochemistry expertise, to develop an exciting portfolio of Targeted Alpha Therapies. Targeted Alpha Therapies hold incredible promise however their development has been hamstrung by a lack of radioisotope supply. Together with the team at AdvanCell, we look forward to writing a new chapter in oncology, to target large patient populations with significant unmet needs.”
Mr Aiudi has been appointed to the Board of AdvanCell, joining Mr Adamovich, Bill Ferris AC, co-founder of CPE Capital, Adrian “Adi” Patterson, former Australian Nuclear Science and Technology Organisation (ANSTO) CEO and Kevin Cameron, CEO of Ionetix.
Bill Ferris AC, Chair remarked, “Our executive team has articulated a credible pre-clinical and clinical pathway for the delivery of the Company’s novel Targeted Alpha Therapies. Having successfully developed the manufacturing platform essential for the reliable and scalable supply of isotopes, the Company is on schedule with its pre-clinical work and is now moving into first-in-human trials. AdvanCell is on track to become a leading radiopharmaceutical company with a platform technology enabling novel cancer treatments.”
About AdvanCell
AdvanCell is a radiopharmaceutical company developing next-generation cancer treatment. AdvanCell’s Targeted Alpha Therapies are powered by a platform technology – a world-first alpha isotope generator that addresses the greatest unmet need in Targeted Alpha Therapy – the reliable and scalable supply of isotope. AdvanCell has a world-class team and is honoured to be advised by an outstanding Board of Directors and Scientific Advisory Board. For more information visit www.advancell.com.au
About Morningside
Founded in 1986 by the Chan family, Morningside is a technology and life science venture investment firm. With offices in Boston, Shanghai and London, the firm invests globally. The group is managed by investment professionals who are entrepreneurial, have deep industry knowledge and are effective in the local environment in which they operate. Morningside partners with academic founders and entrepreneurs to build world-class companies that want to markedly improve the current state of medicine today and ultimately, the lives of patients. In addition to its investment activities, Morningside Ventures is strongly committed to social responsibility. For more information visit www.morningside.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220823005846/en/
Contact information
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
U.S. Bank Investment Services enhances investor and client onboarding experience for alternative investments3.8.2026 15:16:00 EEST | Press release
U.S. Bank Investment Services today announced it has gone live with a new client lifecycle management (CLM) platform, providing a comprehensive onboarding solution for alternative investment clients and the investors in their funds. The implementation is a key milestone in Investment Services’ multi-phased technology transformation strategy, aimed at modernizing processes, workflows and reporting across the private funds space. U.S. Bank leverages CLM provider Fenergo and its Fen-X platform. Fen-X automates many of the manual processes traditionally associated with underlying investors and direct client relationships and accelerates account setup while maintaining regulatory requirements. The enhanced onboarding experience provides investors and clients with more transparency throughout the process and enables integration with other solutions providers involved in the investor journey, such as screening and tax reporting. The investor experience has been further enhanced with an invest
Thales Launches Imperva for AWS to Help Organizations Protect Applications and APIs3.8.2026 15:00:00 EEST | Press release
Thales today announced the availability of Imperva for AWS, bringing its industry-leading web application firewall (WAF) to Amazon Web Services, Inc. (AWS) Marketplace as a SaaS offering. Built on key AWS services, Imperva for AWS helps organizations protect web applications and APIs against common cyber threats and malicious bot activity. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260803503864/en/ ©Thales The 2026 Thales Bad Bot Report found that automated traffic now accounts for 53% of all internet requests, with 27% of bot attacks targeting APIs directly. As attackers increasingly bypass user interfaces to operate at machine speed, organizations need application security that can keep pace without adding complexity. Imperva WAF delivers enterprise-grade protection natively on Amazon CloudFront. Unlike legacy content delivery network WAFs that route traffic outside the cloud provider network, Imperva WAF deploys direc
MEX Exchange, Part of MultiBank Group Strengthens Leadership Team with Key Appointment3.8.2026 14:39:00 EEST | Press release
MEX Exchange, the institutional electronic trading platform of MultiBank Group, today announced the appointment of Vibhanshu Bahuguna as Senior Director, reinforcing the company's commitment to building a world-class leadership team as it expands its global institutional business and technology capabilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260803009139/en/ MEX Exchange, the institutional electronic trading platform of MultiBank Group, today announced the appointment of Vibhanshu Bahuguna as Senior Director, reinforcing the company's commitment to building a world-class leadership team as it expands its global institutional business and technology capabilities. With more than 20 years of experience across sales, business development and electronic trading, Bahuguna joins MEX Exchange with extensive expertise in electronic trading solutions spanning EMS, OMS, OTC and ECN technologies across the foreign exchange
NIQ Returns to IFA 2026 to Lead Industry Conversations on Growth, Innovation, AI and Consumer Transformation3.8.2026 13:45:00 EEST | Press release
As the Official Global Insights Partner of IFA Berlin 2026, NIQ (NYSE: NIQ) will continue to play a leading role shaping industry discussions , bringing together data, AI-driven intelligence, and human insight to illuminate the forces reshaping growth, innovation, and consumer behavior. Through executive keynotes, panel discussions, exclusive market intelligence, and strategic customer engagements (including participation in the IFA Retail Leaders Summit, the fourth NIQ Business Breakfast, and a dedicated SMB-focused event) NIQ will help translate rapid market change into actionable opportunity for the global technology ecosystem. Under this year’s IFA theme, “The Future Is Now,” NIQ will provide timely perspectives on the forces redefining consumer technology, home appliances, and retail—from AI-driven innovation and evolving shopper expectations to omnichannel transformation and emerging growth opportunities. As brands and retailers navigate economic uncertainty, shifting purchase be
Prodalim Reports Q2 2026 Results, with Continued Accelerated Growth in its Specialty Ingredients & Solutions Business3.8.2026 13:03:00 EEST | Press release
Tsahi Barak, Chairman of the Board and CEO of the Company, commented: "We are pleased to report another quarter of growth, highlighted by the increasing contribution of our Specialized Ingredients Solutions (SIS) business. We are clearly seeing the results of the transformation we have been leading over the past year, with revenue from our Specialized Ingredients Solutions business more than doubling compared to the same period last year. The business now contributes approximately 40% of the Group's adjusted EBITDA. We expect this trend to continue gaining momentum, while maintaining the stability and strong performance of our Juice Solutions business. We continue to reinvest the benefits of our growth in strengthening our operational infrastructure, recruiting key talent, and advancing innovative products that are entering commercialization . We believe these investments create a strong foundation for significant operating leverage that has yet to be fully realized, and we expect this
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom